



July 6, 2017

**Re: Update on Spacing of Doses of MenB (Trumenba®) Vaccine**

Dear Texas Vaccines for Children (TVFC) Provider,

On May 19, 2017, the Centers for Disease Control & Prevention (CDC) released a Morbidity & Mortality Weekly Report (MMWR) (available at <https://www.cdc.gov/mmwr/volumes/66/wr/mm6619a6.htm>) that contains updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for the use of 2- and 3-doses of Trumenba®. The recommendations regarding the use of MenB-4C (Bexsero®) are unchanged.

On April 19, 2017, the Texas Department of State Health Services (DSHS) sent a memo to all TVFC providers on the dose scheduling for MenB-FHbp Serogroup B Meningococcal Vaccine (Trumenba®), one of two MenB vaccines. The memo stated:

- “For healthy adolescents who are not at increased risk for meningococcal disease, 2 doses of Trumenba® should be administered at 0 and 6 months. However, if the second dose of Trumenba® is given at an interval of <6 months, a third dose should be given at least 6 months after the first dose; **the minimum interval between the second and third doses is 4 weeks.**”

The recommendations listed in the May 19, 2017 MMWR state:

- “For healthy adolescents who are not at increased risk for meningococcal disease, 2 doses of Trumenba® should be administered at 0 and 6 months. However, if the second dose of Trumenba® is given at an interval of <6 months, **a third dose should be given at least 4 months after the second dose.**”
- In the event that a patient with an incomplete series presents at a clinic and the product previously administered is not available, there should be at least 4 weeks before another MenB product can be administered.



- “For persons > 10 years who are at increased risk for serogroup B meningococcal disease and for use during an outbreak, 3 doses of Trumenba® should be administered at 0, 1-2, and 6 months to provide earlier protection and maximize short-term immunogenicity. However, if the second dose of Trumenba® is administered > 6 months, a third dose is not necessary.”

You are strongly encouraged to immediately implement the changes to the Trumenba® schedule as listed in the MMWR dated May 19, 2017.

The recommendations regarding the use of MenB-4C (Bexsero®) are unchanged.

Thank you for your continued support of the TVFC Program. If you have any questions, please contact the appropriate TVFC Contact listed below.

<b>PINS Beginning With</b>	<b>TVFC Contact</b>	<b>Phone Number</b>
00	City of San Antonio	210-207-3965
01	HSR 1	806-783-6412
02	HSR 2	325-795-5660
03	HSR 3	817-264-4790
04 or 05 <b>not</b> in Hardin, Jefferson or Orange Counties	HSR 4/5N	903-533-5310
05 <b>in</b> Hardin, Jefferson or Orange Counties, 06	HSR 6/5S	713-767-3410
07	HSR 7	254-778-6744
08	HSR 8	210-949-2067
09	HSR 9	432-571-4137
10	HSR 10	915-834-7924
11	HSR 11	956-421-5552
25	City of Houston	832-393-5188

Sincerely,

*Nancy Ejuma*

Nancy Ejuma  
Immunization Unit Director